

ABSTRACT

The invention regards the use of triiodothyronine sulfate, commonly named **T₃S**, as a medicament having thyromimetic activity
5 for the treatment of pathologies due to organic deficiency of triiodothyronine (**T₃**), as such or in association with thyroxine (**T₄**), and pharmaceutical formulations thereof.